0
Cardiovascular Disease |

Do Beta-Blockers Increase Perioperative Cardiac Morbidity?

Pratik Dalal, MBBS; Divyashree Varma, MBBS; Housam Hegazy, MD
Author and Funding Information

SUNY-Upstate Medical University Hospital, Syracuse, NY


Chest. 2013;144(4_MeetingAbstracts):166A. doi:10.1378/chest.1704913
Text Size: A A A
Published online

Abstract

SESSION TITLE: Cardiovascular Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM

PURPOSE: Aim of this study was to assess the risks and benefits of beta-blockers during the perioperative period in patients undergoing non-cardiac surgery.

METHODS: We performed a retrospective cohort analysis of 755 patients in a single university based centre. Patients who had undergone non cardiac surgery were picked at random and sub-classified according to gender, ethnicity, risk of surgery, and whether beta-blockers were used in the perioperative setting. Utilizing the logistic regression model six different outcomes were investigated in this study: all cause mortality, ACS, significant arrhythmias, cardiac event related death, bradycardia and decompensated heart failure. Three variables were used to predict these outcomes: beta-blocker administration, RCRI score, and risk of surgery.

RESULTS: Beta-blocker use was found to increase the odds of having an acute coronary event by a factor of 21.76 (CI: 2.85-?). Decompensated heart failure was also seen to increase by an odds ratio of 4.50 (CI: 1.29-15.70). Surprisingly, risk of arrhythmias was also seen to increase (Odds ratio-2.96; CI: 1.08-4.80). However, due to a small event rate, statistical correctional formulas had to be utilized to stabilize results.

CONCLUSIONS: Our study suggests that beta-blockers may actually increase the risk of having an adverse cardiac event during the perioperative period. Risk of decompensated heart failure and arrhythmias also seems to increase, but to a lesser degree.

CLINICAL IMPLICATIONS: These results becomes especially important in view of the fact that beta-blcokers are currently recommended by the American College of Cardiology/American Heart Association (ACC/AHA) 2011 guidelines regarding peri-operative cardiac risk stratification and management. Benefit may be limited only to the high risk category, including current chronic users and those who would benefit from beta-blocker use by virtue of cardiac pathology, irrespective of surgery.

DISCLOSURE: The following authors have nothing to disclose: Pratik Dalal, Divyashree Varma, Housam Hegazy

No Product/Research Disclosure Information


Sign In to Access Full Content

Want to access your Institution's subscription?
Sign in to your individual user account while you are actively authenticated on this website via your institution (Learn more about institutional authentication). We will then sustain your personal access to their content/subscription for 90 days, after which you can repeat this process.

Sign In to Access Full Content

Want to Purchase a Subscription?

New to CHEST? Become an ACCP member to receive a full subscription to both the print and online editions.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543